期刊文献+

(2R,4R)-4-甲基-2-哌啶甲酸乙酯的合成工艺改进 被引量:3

Synthesis of ethyl(2R,4R)-4-methylpiperidine-2-carboxylate
原文传递
导出
摘要 目的优化(2R,4R)-4-甲基-2-哌啶甲酸乙酯的合成工艺。方法以S-(-)-α-甲基苄胺为原料,与乙醛酸乙酯反应得到[(S)-1-苯乙基亚胺基]乙酸乙酯,与异戊二烯进行环合后,再经不对称氢化和脱保护反应制得(2R,4R)-4-甲基-2-哌啶甲酸乙酯。结果总收率从17.0%提高至47.6%。结论本工艺可有效地降低生产成本。 Objective To optimize the synthesis of ethyl(2R,4R)-4-methylpi-peridine-2-carboxylate.Methods Ethyl(2R,4R)-4-methylpiperidine-2-carboxylate was synthesized from(S)-1-phenylethanamine and ethyl 2-oxoacetate to obtain ethyl [(S)-1-phenylethylimino]acetate,which underwent cyclization with isoprene followed by asymmetric hydrogenation and deprotection.Results The overall yield was improved from 17.0% to 47.6%.Conclusion This method is effective for reducing production costs.
作者 张磊 张灿
出处 《中南药学》 CAS 2012年第8期588-590,共3页 Central South Pharmacy
关键词 (2R 4R)-4-甲基-2-哌啶甲酸乙酯 阿加曲班 凝血酶抑制剂 合成 ethyl(2R,4R)-4-methylpiperidine-2-carboxylate argatroban thrombin inhibitor synthesis
  • 相关文献

参考文献10

  • 1张子彦,张宏卫.阿加曲班研究进展[J].国际内科学杂志,2007,34(8):483-485. 被引量:24
  • 2冯铎.阿加曲班治疗急性脑梗死临床分析[J].中国社区医师(医学专业),2011,13(11):31-31. 被引量:2
  • 3谢智乾,王哲烽,时惠麟.阿加曲班-水合物合成路线图解[J].中国医药工业杂志,2011,42(11):868-872. 被引量:8
  • 4Claude A, Fabrice B. Asymmetric syntheses of enantiopure 4- substituted pipecolic acid derivatives [J]. Eur J Org Chem, 2001, (12): 2385-2389.
  • 5Shosuke O, Akiko H, Ryoji K, et al. N2-Arylsulfonyl-L-argin- inamides and the pharmaceutically acceptable salts thereof: US, 4117127 [P]. 1978-09 26.
  • 6Janine C, Damien B. Direct diastereoselective synthesis of -cis- and -trans-4-methylpipecolic acid and deriva- tives[J]. Tetrahedron Lett, 2001, 42 (11): 2119-2120.
  • 7周跃辉,林国跃,颜伟伟,等.一种(2R,4R)4甲基2-哌啶羧酸化合物的制备方法及其中间体:中国,101712654[P].2010-05-26.
  • 8Carlos A, Ferran S. Enantioselective synthesis of trans-4-meth ylpipecolic acid [J]. J Org Chem, 2007, 72 (20).. 7688-7692.
  • 9Patrizia F, Maria DM. Diastereose[ective synthesis of an ar- gatroban intermediate, ethyl (2R, 4R) - 4-methylpipecolate, by means of a mandyphos/rhodium complex-catalyzed hydro- genation[J]. Tetrahedron Asymmetry, 2011, 22 (16): 1626-1631.
  • 10Karen T, Dominique B. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments: US, 6440417 [P]. 2002-08-27.

二级参考文献35

  • 1袁莉娟,刘爱民,刘蕾.新型凝血酶抑制剂阿加曲班[J].中国新药杂志,2005,14(2):230-234. 被引量:34
  • 2张子彦,张宏卫.阿加曲班研究进展[J].国际内科学杂志,2007,34(8):483-485. 被引量:24
  • 3罗祖明 董佑忠 彭国光.脑血管疾病治疗学[M].北京:人民卫生出版社,2000.384-389.
  • 4Fareed J, Jeske WP, Small-molecule direct antithrombins: argatroban. Best Pract Res Clin Haematol, 2004, 17 ( 1 ) : 127-138.
  • 5Kam PC, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia, 2005,60 ( 6 ) : 565-574.
  • 6Menajovsky LB. Heparin-induced thrombocytopenia: clinical anifestations and management strategies. Am J Med, 2005, 118(Suppl 8A) :21S-30S.
  • 7Serebruany MV, Malinin AI, Serebruany VL Argatroban, a direct thrombin inhibitor for heparin-indueed thrombocytopaenia: present and future perspectives, Expert Opin Pharmacother, 2006,7( 1 ) :81-89,
  • 8Levine RL, Hursting MJ, McCollum D, Argatroban therapy in heparin-induced thrombocytopeina with hepatic dysfunction. Chest, 2006, 129(5) :1167-1175.
  • 9Arnold RJ, Kim R, Tang B. The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment. Cardiol Rev, 2006, 14( 1 ) :7-13.
  • 10Lewis BE, Matthai WH Jr, Cohen M, et al. Argatroban anticoagulation during pereutanceous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovase I nterv, 2002,57 ( 2 ) : 177-184.

共引文献31

同被引文献16

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部